These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 25774553)

  • 1. Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.
    Assini JM; Mulvihill EE; Burke AC; Sutherland BG; Telford DE; Chhoker SS; Sawyez CG; Drangova M; Adams AC; Kharitonenkov A; Pin CL; Huff MW
    Endocrinology; 2015 Jun; 156(6):2087-102. PubMed ID: 25774553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.
    Li Y; Wong K; Giles A; Jiang J; Lee JW; Adams AC; Kharitonenkov A; Yang Q; Gao B; Guarente L; Zang M
    Gastroenterology; 2014 Feb; 146(2):539-49.e7. PubMed ID: 24184811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholic Acid Supplementation of a High-Fat Obesogenic Diet Suppresses Hepatic Triacylglycerol Accumulation in Mice via a Fibroblast Growth Factor 21-Dependent Mechanism.
    Ippagunta SM; Kharitonenkov A; Adams AC; Hillgartner FB
    J Nutr; 2018 Apr; 148(4):510-517. PubMed ID: 29659970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
    Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
    Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α-FGF21 axis in mice.
    Aljohani A; Khan MI; Bonneville A; Guo C; Jeffery J; O'Neill L; Syed DN; Lewis SA; Burhans M; Mukhtar H; Ntambi JM
    J Biol Chem; 2019 Dec; 294(51):19475-19485. PubMed ID: 31690632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid increase in fibroblast growth factor 21 in protein malnutrition and its impact on growth and lipid metabolism.
    Ozaki Y; Saito K; Nakazawa K; Konishi M; Itoh N; Hakuno F; Takahashi S; Kato H; Takenaka A
    Br J Nutr; 2015 Nov; 114(9):1410-8. PubMed ID: 26330054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary medium-chain fatty acids reduce hepatic fat accumulation via activation of a CREBH-FGF21 axis.
    Cao Y; Araki M; Nakagawa Y; Deisen L; Lundsgaard A; Kanta JM; Holm S; Johann K; Brings Jacobsen JC; Jähnert M; Schürmann A; Kiens B; Clemmensen C; Shimano H; Fritzen AM; Kleinert M
    Mol Metab; 2024 Sep; 87():101991. PubMed ID: 39019116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrocapsiate supplementation prevented high-fat diet-induced adiposity, hepatic steatosis, glucose intolerance, and gut morphological alterations in mice.
    Baboota RK; Khare P; Mangal P; Singh DP; Bhutani KK; Kondepudi KK; Kaur J; Bishnoi M
    Nutr Res; 2018 Mar; 51():40-56. PubMed ID: 29673543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.
    Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR
    Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor γ coactivator-1α-deficient mice.
    Fletcher JA; Linden MA; Sheldon RD; Meers GM; Morris EM; Butterfield A; Perfield JW; Rector RS; Thyfault JP
    Exp Physiol; 2018 Mar; 103(3):408-418. PubMed ID: 29215172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
    Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J
    Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
    Mulvihill EE; Assini JM; Sutherland BG; DiMattia AS; Khami M; Koppes JB; Sawyez CG; Whitman SC; Huff MW
    Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):742-8. PubMed ID: 20110573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism.
    Xie T; So WY; Li XY; Leung PS
    Clin Sci (Lond); 2019 Oct; 133(19):2029-2044. PubMed ID: 31654570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.
    Lin Z; Tian H; Lam KS; Lin S; Hoo RC; Konishi M; Itoh N; Wang Y; Bornstein SR; Xu A; Li X
    Cell Metab; 2013 May; 17(5):779-89. PubMed ID: 23663741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.
    Goto T; Hirata M; Aoki Y; Iwase M; Takahashi H; Kim M; Li Y; Jheng HF; Nomura W; Takahashi N; Kim CS; Yu R; Seno S; Matsuda H; Aizawa-Abe M; Ebihara K; Itoh N; Kawada T
    J Biol Chem; 2017 Jun; 292(22):9175-9190. PubMed ID: 28404815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver.
    Hotta Y; Nakamura H; Konishi M; Murata Y; Takagi H; Matsumura S; Inoue K; Fushiki T; Itoh N
    Endocrinology; 2009 Oct; 150(10):4625-33. PubMed ID: 19589869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling.
    Kaneko H; Anzai T; Nagai T; Anzai A; Takahashi T; Mano Y; Morimoto K; Maekawa Y; Itoh H; Yoshikawa T; Ogawa S; Fukuda K
    Cardiovasc Res; 2011 Aug; 91(3):546-55. PubMed ID: 21447704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.
    Mulvihill EE; Allister EM; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Markle JM; Hegele RA; Huff MW
    Diabetes; 2009 Oct; 58(10):2198-210. PubMed ID: 19592617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.